Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 24, 2019 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference

WAYNE, Pa., May 24, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
May 08, 2019 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments

Submitted IND for ATI-450, an oral MK2 inhibitorRHOFADE net sales of $3.7 million for the first quarter of 2019Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., May 08, 2019 (GLOBE...
May 01, 2019 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019

WAYNE, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
April 25, 2019 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis

WAYNE, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
April 24, 2019 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata

WAYNE, Pa., April 24, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
March 27, 2019 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Attend Upcoming Investor Conference

WAYNE, Pa., March 27, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today...
March 18, 2019 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments

Product Sales of $3.9 Million for Fiscal Year 2018Initiates Financial Guidance for Full Year 2019Management to Host Conference Call at 8:00 AM ET today WAYNE, Pa., March 18, 2019 (GLOBE NEWSWIRE)...
March 08, 2019 16:54 ET | Source: Aclaris Therapeutics, Inc.

CORRECTION - Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019

WAYNE, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Aclaris Therapeutics, Inc. (NASDAQ: ACRS) please note that in the first paragraph of the...
March 08, 2019 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019

WAYNE, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today...
February 28, 2019 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg

WAYNE, Pa., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases,...